Enterprise Value to EBITDA Ratio: Actuate Therapeutics, Inc. (ACTU)
Actuate Therapeutics, Inc. (ACTU) generates revenue by attracting investments to create cutting-edge drugs for combating resistant tumors. The company is developing specific GSK-3beta inhibitors, which offer the advantages of minimal toxic impact and patent protection. The share price retrospective on GURU.Markets shows an EV/EBITDA of 0.00, while the business remains exposed to high risks due to its concentration on a single drug during trials.
Metric breakdowns and analytics for Actuate Therapeutics (ACTU)
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Actuate Therapeutics, Inc.|ACTU - Long-Term Debt to Capital|Short-Term Debt to Capital Actuate Therapeutics Inc|ACTU - Company Total Debt|Debt to Book Value Actuate Therapeutics Inc|ACTU - Amount of Long-Term Liabilities|Company Current Liabilities Actuate Therapeutics|Quick Ratio actuatetherapeutics.com
- business earnings and investment ratios data:
ACTU - Net Profit|Future Profit Actuate Therapeutics, Inc.|ACTU - Market Price to Net Income Ratio|Forward P/E Multiple Actuate Therapeutics Inc|ACTU - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Actuate Therapeutics Inc.|ACTU - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Actuate Therapeutics|ACTU - Earnings per share for the last four quarters|Quarterly EPS earnings growth actuatetherapeutics.com|ACTU - Earnings per share increase in current year|Earnings growth forecast for next year Actuate Therapeutics, Inc.
- company sales and revenue statistics:
Analysis of all company metrics:Actuate Therapeutics, Inc (ACTU)
The fundamental attractiveness of Actuate Therapeutics, Inc. (ACTU) is determined through the prism of business value relative to its operational efficiency. This Enterprise Value to EBITDA ratio on GURU.Markets compares market capitalization, adjusted for debt, against EBITDA to identify the asset's true floor. The metric measures the investment payback period by excluding the impact of taxes and depreciation. For Actuate Therapeutics, Inc. (ACTU) and its promising oncology pipeline, this indicator confirms the market's vote of confidence in future cash flows.
Competing companies
BeiGene Oncology - Enterprise Value to EBITDA Ratio|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology Corp (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen - Business Value to Operating Income Before Depreciation|BCAX (Bicara Therapeutics Inc) - EV/EBITDA Multiple|Company Value to EBITDA personalis.com PSNL|EV/EBITDA Multiple ERAS|Delcath Systems - Enterprise Value to Operating Income Before Depreciation|Y-mAbs Therapeutics Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Aura Corp AURA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Accuray (ARAY) - Enterprise Value to EBITDA Ratio|SLS: EV/EBITDA Multiple|CTOR - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tuhurabio.com|EV/EBITDA Multiple Protara Tx|Enterprise Value to EBITDA Ratio FATE (Fate Therapeutics Corp)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization WHWK (Aadi Bioscience)|TScan Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Champions Oncology (CSBR) - Company Value to EBITDA|XBiotech - EV/EBITDA Multiple|CEL-SCI (CVM) - Enterprise Value to EBITDA Ratio|OS Therapies Inc (OSTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|radiopharmtheranostics.com - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artiva Biotherapeutics Inc.|Company Value to EBITDA Adlai Nortye Ltd. ANL|EV/EBITDA Multiple VERU|TPST - Company Value to EBITDA|EV/EBITDA Multiple XLO (Xilio Therapeutics)|RENB - Enterprise Value to EBITDA Ratio|muraloncology.com - EV/EBITDA Multiple|KAPA - EV/EBITDA Multiple|OKUR: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio GDTC (CytoMed Therapeutics Ltd)|CRIS (curis.com) - EV/EBITDA Multiple|Apollomics, Inc. (APLM) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio THAR (Tharimmune, Inc.)|ADVB (Advanced Biomed) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple GNPX (Genprex Inc)|calidibio.com (CLDI) - Company Value to EBITDA|sunshinebiopharma.com - EV/EBITDA Multiple|Company Value to EBITDA Xenetic Biosciences, Inc.|SLRX (Salarius Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Ratio Purple Biotech Ltd.|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio BeOne Medicines (BGNE)|EV/EBITDA Multiple CKPT|ELEV - Company Value to EBITDA|iCAD Inc. - Enterprise Value to EBITDA Ratio|IKNA: Enterprise Value to Operating Income Before Depreciation|Notable Labs Ltd - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics Inc.)|MorphoSys AG (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio NAYA Biosciences|AAPGV (ascentage.com) - EV/EBITDA Multiple
